Molecular medicine of fragile X syndrome: based on known molecular mechanisms
Shi-Yu Luo1, Ling-Qian Wu1, Ran-Hui Duan2
1State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, Changsha, China.
Background:
Extensive research on fragile X mental retardation gene knockout mice and mutant Drosophila models has largely expanded our knowledge on mechanism-based treatment of fragile X syndrome (FXS). In light of these findings, several clinical trials are now underway for therapeutic translation to humans.
Data Sources:
Electronic literature searches were conducted using the PubMed database and ClinicalTrials.gov. The search terms included "fragile X syndrome", "FXS and medication", "FXS and therapeutics" and "FXS and treatment". Based on the publications identified in this search, we reviewed the neuroanatomical abnormalities in FXS patients and the potential pathogenic mechanisms to monitor the progress of FXS research, from basic studies to clinical trials.
Results:
The pathological mechanisms of FXS were categorized on the basis of neuroanatomy, synaptic structure, synaptic transmission and fragile X mental retardation protein (FMRP) loss of function. The neuroanatomical abnormalities in FXS were described to motivate extensive research into the region-specific pathologies in the brain responsible for FXS behavioural manifestations. Mechanism-directed molecular medicines were classified according to their target pathological mechanisms, and the most recent progress in clinical trials was discussed.
Conclusions:
Current mechanism-based studies and clinical trials have greatly contributed to the development of FXS pharmacological therapeutics. Research examining the extent to which these treatments provided a rescue effect or FMRP compensation for the developmental impairments in FXS patients may help to improve the efficacy of treatments.
Insights
Research on fragile X syndrome (FXS) using animal models has led to mechanism-based treatments. Clinical trials are now exploring these therapies to improve outcomes for FXS patients.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Fragile X syndrome (FXS) research has advanced significantly through studies of knockout mice and mutant Drosophila.
- This foundational research has paved the way for mechanism-based therapeutic strategies for FXS.
Purpose of the Study:
- To review neuroanatomical abnormalities and pathogenic mechanisms in FXS.
- To track the progress of FXS research from basic science to clinical trials.
- To categorize mechanism-directed molecular medicines for FXS.
Main Methods:
- Electronic literature searches of PubMed and ClinicalTrials.gov.
- Review of publications on FXS, medication, therapeutics, and treatment.
- Analysis of neuroanatomical abnormalities and pathogenic mechanisms.
Main Results:
- Pathological mechanisms of FXS were categorized by neuroanatomy, synaptic structure, transmission, and FMRP loss of function.
- Neuroanatomical abnormalities in FXS were linked to region-specific brain pathologies and behavioral manifestations.
- Mechanism-directed therapies were classified, and clinical trial progress was discussed.
Conclusions:
- Mechanism-based studies and clinical trials are crucial for developing FXS pharmacological treatments.
- Further research on treatment efficacy, including rescue effects and FMRP compensation, is needed to improve patient outcomes.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
Related Concept Videos
01:43Sex-linked Disorders
01:29Pharmacogenomics: Identification of New Drug Targets